文献速递冠心病血脂与心血管预防

西雅图心绞痛问卷作为临床试验与临床结局指标的解讀:综述

Interpretation of the Seattle Angina Questionnaire as an Outcome Measure in Clinical Trials and Clinical Care: A Review.
PubMed 文献 · JAMA Cardiol · 2021-01-01

该综述阐述如何解读西雅图心绞痛问卷(SAQ),介绍其构建与表面效度,重点将分值与分值变化对齐临床构念;SAQ心绞痛频率量表0-30分示每日心绞痛、31-60分示每周、61-99分示每月、100分示无心绞痛;临床试验除报告组间均值差外,还应报告获得临床重要获益的患者分布以生成需治疗人数。

要点

  • SAQ心绞痛频率量表:0-30分每日、31-60分每周、61-99分每月、100分无心绞痛。
  • 临床试验应报告获得临床重要获益的患者分布,以生成需治疗人数。
  • SAQ广泛使用源于其效度、可重复性、预后重要性及对临床变化的敏感性。

核心结论

  • SAQ广泛使用源于其已确立的效度、可重复性、预后重要性及对临床变化的敏感性。
  • 解读SAQ的挑战在于对其各领域临床重要性不熟悉,无论横断面或纵向。

研究设计与样本

  • 综述,阐述SAQ的解读、构建与表面效度,聚焦分值与分值变化对齐临床构念。

主要发现

  • SAQ问题与经验丰富的临床医生对稳定缺血性心脏病患者所问相似。
  • SAQ心绞痛频率量表0-30分示每日心绞痛,31-60分示每周,61-99分示每月,100分示无心绞痛。
  • 分值变化可通过对齐问题回答的变化来描述。

关键数值与推荐

  • SAQ心绞痛频率量表0-30分指示每日心绞痛,31-60分指示每周,61-99分指示每月,100分指示无心绞痛。
  • 临床试验除报告治疗组间均值差外,还应报告获得临床重要获益的患者分布以生成需治疗人数。

临床怎么用

  • 将SAQ分值与临床构念对齐以解读患者心绞痛频率与生活质量影响。
  • 在临床试验中同时报告组间均值差与获得临床重要获益的患者分布。
  • 将SAQ作为以患者为中心的 care 工具及人群健康策略手段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patient-reported outcomes are increasingly used as end points in clinical trials, assessments in clinical care, and tools for population health, with an increasing role in quality assessment. For patients with coronary artery disease, the Seattle Angina Questionnaire (SAQ) has emerged as the most commonly used measure of disease-specific health status to quantify patients' symptoms of angina and the extent to which their angina affects their functioning and quality of life. This review explains how to interpret the SAQ and describes the construction and face validity of the SAQ, focusing on aligning scores and changes in scores with clinical constructs. OBSERVATIONS: The SAQ asks questions similar to those an experienced clinician would ask of a patient with stable ischemic heart disease. Therefore, SAQ scores can be aligned with clinical constructs (eg, scores on the SAQ angina frequency scale of 0-30 points indicate daily angina, 31-60 points indicate weekly angina, 61-99 points indicate monthly angina, and 100 points indicate no angina), and changes in scores can be described by aligning them with changes in question responses. After clinical thresholds are defined, it is important for clinical trials to not simply report mean differences between treatment arms but to also report the distributions of patients who have had clinically important benefits so that a number needed to treat can be generated. CONCLUSIONS AND RELEVANCE: The widespread use of the SAQ is a consequence of its well-established validity, reproducibility, prognostic importance, and sensitivity to clinical change. Nevertheless, interpreting the SAQ can be challenging because of lack of familiarity with the clinical importance of its domains, either cross-sectionally or longitudinally. This review provides an overview of the interpretability of the SAQ as a foundation for its use as an end point in clinical trials, a tool to support more patient-centered care, and a means of facilitating population health strategies to provide a better foundation for the integration of patient experiences with clinical care.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Thomas M, Jones PG, Arnold SV, et al. Interpretation of the Seattle Angina Questionnaire as an Outcome Measure in Clinical Trials and Clinical Care: A Review. JAMA Cardiol. 2021. PMID: 33566062. doi:10.1001/jamacardio.2020.7478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。